The company said it will use the proceeds to develop new liquid biopsy tests to predict drug response in cancer patients.
Premier is a healthcare group purchasing organization representing about 4,000 hospitals and 165,000 other providers throughout the US.
The companies initially expect to incorporate a CDx for Incyte's pemigatinib into Foundation Medicine's existing FDA-approved assay, FoundationOne CDx.
Expedeon's colloidal gold is an aqueous suspension of uniform, spherical metallic nanoparticles that can conjugate to antibodies and antigens.
Lunaphore's LabSat Frozen technology aims to automate biomarker-specific frozen section staining and enable performing IHC assays within minutes.
In its response, the company accused the Securities and Exchange Commission's lawsuit of containing "serious factual inaccuracies."
The assay will combine the company's CytoSort assay with its automated AIR system for imaging, sorting, and isolating single cells and small colonies.
The BD business, which has annual revenues of about $100 million, offers technical services as well as peptones for cell culture media used in biopharmaceutical applications.
The company said it plans to list its stock on the Nasdaq under the ticker symbol GH.
The firm reported a 69 percent increase in product sales, driven by a 102 percent jump in cartridge sales and jump in research revenues.
In an email, the company's CEO said it is running out of funds and has been unable to find new investors — the shutdown could start on Sept. 10.
The study is testing the efficacy of cancer treatments that are selected based on genomic markers driving patients' tumors, regardless of cancer type.
The biomarker profiling project is expected to enable a better understanding of how lifestyle, environment, and genetics combine to cause diseases.
The new agreement amends a deal reached in October to partially fund its acquisition of some Alere businesses. That agreement was for $270 million.
CareDx and Invitae each had massive share-price gains last month. Exact Sciences, GenMark, and Natera also saw sizeable increases in their stock prices.
The two firms will provide €14M ($16.2 million) of equity funding to commercialize the Idylla platform in the Chinese market.
Veracyte said that the draft policy is open to a 45-day comment period and could potentially go into effect in early 2019.
The firm's microfluidic diagnostic system uses phenotypic bacteria growth analysis to enable rapid antibiotic testing and treatment of sepsis patients.
Excluding the impact of the one-time sale of patents last year, the company's revenues climbed 38 percent on strong product and service revenue growth.
The acquisition of the workplace wellness company's assets is set to take place following Provant Health's bankruptcy auction.